Commentary

Article

State of the Science Summit - Breast Cancer: Chaired by Hatem Soliman MD

State of the Science Summit - Breast Cancer: Chaired by Hatem Soliman MD

State of the Science Summit - Breast Cancer: Chaired by Hatem Soliman MD

Speakers

  • Hatem Soliman, MD | Moffitt Cancer Center
  • Avan Armaghani, MD, FACP | Moffitt Cancer Center
  • Hyo Han, MD | Moffitt Cancer Center
  • Aixa Soyano Muller, MD | Moffitt Cancer Center
  • Pavan Kumar Tandra, MD | Moffitt Cancer Center
  • Tracey O’Connor, MD | Moffitt Cancer Center

Topics

  • CDK4/6i plus ET in HR+/HER2- Breast Cancers
  • Case Presentation: Frontline HR+/HER2- mBC
  • Best Practices in the Management of HR+ Breast Cancers
  • Sequencing Beyond CDK4/6 Inhibitors
  • Case Presentation 2: Sequencing and 2L+ mBC
  • Dosing of CDK4/6i in real world patients and efficacy

Interested in attending a live or virtual event? Click here to register for an upcoming webinar.

Some of the episodes from our podcast, OncLive On Air, are focused on the interviews with faculty conducted at the State of the Science SummitsClick here to listen to our latest episodes!

Related Videos
Jason Abdou Mouabbi, MD, assistant professor, Department of Breast Medical Oncology, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Antonio Llombart-Cussac, MD, PhD
Joyce O'Shaughnessy, MD
Adrienne G. Waks, MD,
David Rimm, MD, PhD
This series features 2 KOLs
This series features 2 KOLs
Trastuzumab deruxtecan vs physician’s choice of chemotherapy in patients with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–low or HER2-ultralow metastatic breast cancer with prior endocrine therapy: primary results from DESTINY-Breast06
4 KOLs are featured in this series.
4 KOLs are featured in this series.